Effect of Mannan Oligosaccharides Extracts in Uropathogenic Escherichia coli Adhesion in Human Bladder Cells

Urinary tract infections (UTIs) are a common public health problem, mainly caused by uropathogenic Escherichia coli (UPEC). Patients with chronic UTIs are usually treated with long-acting prophylactic antibiotics, which promotes the development of antibiotic-resistant UPEC strains and may complicate their long-term management. D-mannose and extracts rich in D-mannose such as mannan oligosaccharides (MOS; D-mannose oligomers) are promising alternatives to antibiotic prophylaxis due to their ability to inhibit bacterial adhesion to urothelial cells and, therefore, infection. This highlights the therapeutic potential and commercial value of using them as health supplements. Studies on the effect of MOS in UTIs are, however, scarce. Aiming to evaluate the potential benefits of using MOS extracts in UTIs prophylaxis, their ability to inhibit the adhesion of UPEC to urothelial cells and its mechanism of action were assessed. Additionally, the expression levels of the pro-inflammatory marker interleukin 6 (IL-6) were also evaluated. After characterizing their cytotoxic profiles, the preliminary results indicated that MOS extracts have potential to be used for the handling of UTIs and demonstrated that the mechanism through which they inhibit bacterial adhesion is through the competitive inhibition of FimH adhesins through the action of mannose, validated by a bacterial growth impact assessment.

Automated summary

Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli remain a common public health problem. Long-acting prophylactic antibiotics are commonly used in the treatment of chronic UTIs, but they contribute to the development of antibiotic-resistant strains. D-mannose and mannose oligosaccharides (MOS) have the potential to serve as alternatives to antibiotic prophylaxis due to their ability to inhibit bacterial adhesion and infection. However, research on the effect of MOS in UTIs is limited. Preliminary results suggest that MOS extracts have the potential to be used in UTIs management by competitively inhibiting bacterial adhesion through mannose action.